Full Title
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)Purpose
Researchers are comparing two different drugs for people with advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that spread and has not yet been treated.
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
If you join this study, you will be randomly assigned to get neladalkib (NVL-655) or the standard treatment, alectinib. Both drugs are taken orally (by mouth). They each target the ALK protein, which is made by the ALK gene. By blocking the ALK protein, the treatment may stop your cancer cells from growing and spreading.
Who Can Join
To join this study, there are a few conditions. You must:
- Have ALK-positive NSCLC that has spread and has not yet been treated.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Alexander Drilon’s office at 646-608-3758.